Clinical DevelopmentArcus Biosciences is on track to initiate its Phase 3 PEAK-1 study after a recent positive FDA meeting, indicating progress in its clinical development plans.
Market PotentialCasdatifan is believed to have best-in-class potential, which could drive stock upside.
Partnership OpportunitiesArcus Biosciences announced a clinical collaboration with AZN for the development of its HIF-2α inhibitor in combination with a PD-1 x CTLA-4 bispecific, which could broaden opportunities in advanced cancer treatments.